RK
Insider
Reshma Kewalramani
CEO & PresidentReshma Kewalramani (CEO & President) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Vertex Pharmaceuticals Incorporated (VRTX). The largest single filing was $19.7M of VRTX (39,880 sh across 12 lots, as filed), executed Feb 27.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$19.7M
shares × price, as filed
Last traded
Feb 27
Filed Mar 3
Median ADV $756.7M across their filed names
Open performance→Volume by month
Buys $3.9M
Sells $27.5M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
VRTX
Vertex Pharmaceuticals Incorporated
VRTX · 1 buy · 2 sells
3 filings
Recent filings
VRTXSALE
Vertex Pharmaceuticals Incorporated
View filing →
$19.7M39,880 sh across 12 lots
Exec Feb 27
Filed Mar 3 · 5:30 PM ET VRTXPURCHASE Vertex Pharmaceuticals Incorporated View filing → $3.9M
10,000 sh across 2 lots
Exec Aug 6 2025
Filed Aug 7 2025 · 4:23 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated View filing → $7.8M
15,198 sh × $515.00
Exec Nov 8 2024
Filed Nov 12 2024 · 5:30 PM ET